RLM-MD-04 Diabetic Gastroparesis

A 52-week, randomized, double-blind, placebo-controlled, Phase 3 study to evaluate the safety and efficacy of Relamorelin in patients with Diabetic Gastroparesis who present with no vomiting at screening.

Product: Relamorelin (also known as RM-131) is a novel, potent, and selective penta-peptide ghrelin analogue, which is being developed for treatment of diabetic gastroparesis (DG).

Sponsor: Allergan

Principal Investigator: Dr. William Holderman